BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29100435)

  • 1. Effect of TALEN-mediated IL-6 knockout on cell proliferation, apoptosis, invasion and anti-cancer therapy in hepatocellular carcinoma (HCC-LM3) cells.
    Zhuang PY; Zhang KW; Wang JD; Zhou XP; Liu YB; Quan ZW; Shen J
    Oncotarget; 2017 Sep; 8(44):77915-77927. PubMed ID: 29100435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
    Kong J; Kong F; Gao J; Zhang Q; Dong S; Gu F; Ke S; Pan B; Shen Q; Sun H; Zheng L; Sun W
    Mol Cancer; 2014 Jan; 13():7. PubMed ID: 24418169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-α enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma.
    Wang CJ; Xiao CW; You TG; Zheng YX; Gao W; Zhou ZQ; Chen J; Xue XB; Fan J; Zhang H
    Mol Cancer; 2012 May; 11():31. PubMed ID: 22569271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction.
    He B; Dai L; Zhang X; Chen D; Wu J; Feng X; Zhang Y; Xie H; Zhou L; Wu J; Zheng S
    Int J Biol Sci; 2018; 14(13):1845-1858. PubMed ID: 30443188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
    Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
    Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of interleukin-32α promotes invasion by modulating VEGF in hepatocellular carcinoma.
    Zhao WB; Wang QL; Xu YT; Xu SF; Qiu Y; Zhu F
    Oncol Rep; 2018 Mar; 39(3):1155-1162. PubMed ID: 29286122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib promotes hepatocellular carcinoma invasion
    Zhuang P; Wang D; Zhang K; Wang J; Shen J
    J Cancer; 2023; 14(10):1859-1874. PubMed ID: 37476196
    [No Abstract]   [Full Text] [Related]  

  • 9. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
    Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
    J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
    Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
    World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 17β-estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling.
    Lee S; Lee M; Kim JB; Jo A; Cho EJ; Yu SJ; Lee JH; Yoon JH; Kim YJ
    Biochem Biophys Res Commun; 2016 May; 473(4):1247-1254. PubMed ID: 27091428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma.
    Gu FM; Li QL; Gao Q; Jiang JH; Zhu K; Huang XY; Pan JF; Yan J; Hu JH; Wang Z; Dai Z; Fan J; Zhou J
    Mol Cancer; 2011 Dec; 10():150. PubMed ID: 22171994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy.
    Wu JM; Sheng H; Saxena R; Skill NJ; Bhat-Nakshatri P; Yu M; Nakshatri H; Maluccio MA
    Cancer Lett; 2009 Jun; 278(2):145-155. PubMed ID: 19303700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The inhibition effects of apatinib on cell proliferation, migration and apoptosis in esophageal carcinoma via Ras/Raf/MEK/ERK and JAK2/STAT3 pathways].
    Feng Y; Zhou MY; Sun F; Kong Z; Wang J; Sun ZQ; Hu LJ; Wang JL; Hua Q; Yu JP
    Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):263-275. PubMed ID: 31014051
    [No Abstract]   [Full Text] [Related]  

  • 16. [Anti-proliferation effect of sorafenib in combination with 5-FU for hepatocellular carcinoma in vitro: antagonistic performance and mechanism].
    Deng LF; Wang YH; Jia QA; Ren ZG; Shen HJ; Sun XJ; Li JH
    Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):845-9. PubMed ID: 24331695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NLRC3 silencing accelerates the invasion of hepatocellular carcinoma cell via IL-6/JAK2/STAT3 pathway activation.
    Kang JH; Li MJ; Luan PP; Jiang DK; Chen YW; Xu X; Yu Q; Xu YW; Su Q; Peng WH; Jian WX
    Cell Biol Int; 2020 Oct; 44(10):2053-2064. PubMed ID: 32584509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells.
    Yao X; Zhao CR; Yin H; Wang K; Gao JJ
    Acta Pharmacol Sin; 2020 Dec; 41(12):1609-1620. PubMed ID: 32300243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma.
    Dai Z; Wang X; Peng R; Zhang B; Han Q; Lin J; Wang J; Lin J; Jiang M; Liu H; Lee TH; Lu KP; Zheng M
    Cancer Lett; 2022 Jan; 524():161-171. PubMed ID: 34687791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer activity of dietary xanthone α-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1.
    Zhang H; Tan YP; Zhao L; Wang L; Fu NJ; Zheng SP; Shen XF
    Cell Death Dis; 2020 Jan; 11(1):63. PubMed ID: 31980595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.